Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
|
Update on Hepcidin Regulation in Different Disorders
The discovery of hepcidin has been a major breakthrough in our understanding of iron metabolism. In this webcast, Dr. Pierre Brissot will introduce you to the role of hepcidin at the molecular, cellular, and systemic levels. The critical importance of hepcidin will become clear as he demonstrates the clinical implications of hepcidin modulation in the pathophysiology of acquired and genetic iron-related disorders. Join Dr. Brissot for "Update on Hepcidin Regulation in Different Disorders" and learn about the role of hepcidin in iron dysregulation due to sickle cell disease, thalassaemia, myelodysplastic syndromes, polymetabolic syndrome, alcoholism, hepatitis C virus infection, and more.
|
|
Faculty
|
|
|
Pierre Brissot, MD
Professor of Medicine
Liver Disease Department
University Hospital Pontchaillou
Rennes, France
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of patients with genetic forms of iron deficiency anaemia.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Apply knowledge of hepcidin transcription, cellular targets, and physiologic action to the pathogenesis and clinical manifestations of acquired and genetic iron-related disorders, including sickle cell disease, thalassaemia, myelodysplastic syndromes, and others.
|
Disclosure Information
Pierre Brissot, MD, has received grant/research support from and is on the speakers bureau of Novartis Pharmaceuticals Corporation. Prof. Brissot has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.
|
|
|
|
|
|
|
